Markus Kosch, MD, is the head of Oncology Europe at Daiichi Sankyo. In this role, he leads the medical affairs, market access and commercial organization of Daiichi Sankyo in the European countries. Dr Kosch has over 15 years` experience in the pharmaceutical industry, starting in Medical Affairs at Wyeth Pharmaceutical introducing the first mTOR inhibitor in oncology therapy and later at Pfizer leading the European teams preparing launches in hematology and in personalized therapy in lung cancer with molecular-targeted medicines as well as introducing the first CDK4,6 inhibitor in metastatic breast cancer. Before joining Daiichi Sankyo he led the global Immunooncology, kidney and lung cancer franchise at Pfizer.
After studies as medical student that took him to Kings College London and the UCSF in San Francisco he obtained his medical degree at the University of Münster, Germany. He is a boarded expert in internal medicine and nephrology and practiced in internal medicine, intensive care, and oncology at the University Hospital Münster until 2005. He has published many peer-reviewed papers, reviews and book chapters and still teaches as Professor of Internal Medicine at the Medical School Münster. He is also a founding member of the “Vision Zero” oncology prevention initiative and think tank.
Updated: October 2021